Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes
Cells · 25.05.2023 · 12 (11) · 1472
DOI: 10.3390/cells12111472 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cells, online erschienen am 25.05.2023. Verfasst von Nida Ajmal und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 1, Insulin-Secreting Cells, Islets of Langerhans. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Type 1 diabetes (T1D) is a chronic autoimmune disorder that damages beta cells in the pancreatic islets of Langerhans and results in hyperglycemia due to the loss of insulin. Exogenous insulin therapy can save lives but does not halt disease progression. Thus, an effective therapy may require beta-cell restoration and suppression of the autoimmune response. However, currently, there are no treatment options available that can halt T1D. Within the National Clinical Trial (NCT) database, a vast majority of over 3000 trials to treat T1D are devoted to insulin therapy. This review focuses on non-insulin pharmacological therapies. Many investigational new drugs fall under the category of immunomodulators, such as the recently FDA-approved CD-3 monoclonal antibody teplizumab. Four intriguing candidate drugs fall outside the category of immunomodulators, which are the focus of this review. Specifically, we discuss several non-immunomodulators that may have more direct action on beta cells, such as verapamil (a voltage-dependent calcium channel blocker), gamma aminobutyric acid (GABA, a major neurotransmitter with effects on beta cells), tauroursodeoxycholic acid (TUDCA, an endoplasmic reticulum chaperone), and volagidemab (a glucagon receptor antagonist). These emerging anti-diabetic drugs are expected to provide promising results in both beta-cell restoration and in suppressing cytokine-derived inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.
- Translational Biomedical Sciences Graduate Program, Ohio University, Athens, OH 45701, USA.
- Honors Tutorial College, Ohio University, Athens, OH 45701, USA.
- Molecular and Cellular Biology Graduate Program, Ohio University, Athens, OH 45701, USA.
ORCID-Profile: Nida Ajmal, Maislin C Bogart, Palwasha Khan, Ibiagbani M Max-Harry, Craig S Nunemaker
Zitieren
APA
Ajmal, N., Bogart, M. C., Khan, P., Max-Harry, I. M., & Nunemaker, C. S. (2023). Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes. Cells, 12(11), 1472. https://doi.org/10.3390/cells12111472
Vancouver
Ajmal N, Bogart MC, Khan P, Max-Harry IM, Nunemaker CS. Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes. Cells. 2023;12(11):1472. doi:10.3390/cells12111472
BibTeX
@article{Ajmal2023,
author = {Ajmal, Nida and Bogart, Maislin C and Khan, Palwasha and Max-Harry, Ibiagbani M and Nunemaker, Craig S},
title = {Emerging Anti-Diabetic Drugs for Beta-Cell Protection in Type 1 Diabetes},
journal = {Cells},
year = {2023},
volume = {12},
number = {11},
pages = {1472},
doi = {10.3390/cells12111472}
}
EUVIMED